Oleander Extract Glioblastoma Study Retracted Over Image Integrity Concerns

A once-promising chapter in botanical cancer research has come to an abrupt end. Frontiers in Pharmacology has formally retracted a 2020 study that reported…

The retraction of this study underscores how the peer-review process, while rigorous, is not infallible. When the original paper appeared in September 2020, it joined a growing body of literature examining whether compounds derived from plants could be repurposed as anticancer therapeutics. The idea that a common ornamental plant might harbor molecules capable of attacking one of the most lethal human cancers captured considerable attention. Glioblastoma, the aggressive brain tumor at the center of the research, has long frustrated oncologists, with median survival for patients typically measured in months despite surgery, radiation, and chemotherapy. Any claim of a compound that could suppress glioblastoma growth while also targeting the signaling pathways thought to drive tumor recurrence was therefore met with significant interest from researchers seeking new options for a disease with remarkably few approved treatments.

Supercritical carbon dioxide extraction, the technique used to produce the botanical drug in the study, is a method worth understanding in its own right. Unlike conventional solvent-based extraction, supercritical CO2 extraction uses carbon dioxide held at a temperature and pressure where it behaves as both a liquid and a gas, allowing it to dissolve compounds from plant material with high efficiency. When the pressure is released, the carbon dioxide simply evaporates, leaving behind a concentrated extract free of residual solvent contamination. This property has made the technique especially attractive for preparing botanical drugs intended for human use, since it aligns with the purity expectations of regulatory agencies. Oleander extracts prepared this way had previously been the subject of early-phase clinical investigation, which lent the retracted study an air of translational relevance beyond basic laboratory science.

The biological rationale behind the research also merited attention. The Akt/mTOR signaling pathway is a central regulator of cell growth, proliferation, and survival, and it is frequently hyperactivated in glioblastoma. Drugs that inhibit components of this pathway have been explored extensively, though single-agent mTOR inhibitors have generally produced disappointing results in clinical trials for brain tumors, partly because of the pathway’s redundancy and the blood-brain barrier’s exclusion of many compounds. A plant-derived extract that appeared to suppress this axis offered a potentially different approach, since complex botanical mixtures contain multiple bioactive constituents that may act on several targets simultaneously. The reported effects on glioma stem-like cells added further significance, as these slow-dividing cell populations are widely believed to contribute to treatment resistance and tumor recurrence after standard therapy.

The way this retraction came about reflects broader changes in how scientific integrity issues are identified and addressed. The notice specifically credits Sholto David, an independent researcher who has become known for systematically examining published figures in cancer biology papers and alerting journals to potential problems. This form of post-publication peer review has grown increasingly influential in recent years. Sophisticated image analysis tools and public forums allow researchers unaffiliated with a paper to scrutinize western blots, microscopy panels, and other graphical data for signs of duplication, splicing, or manipulation. What once might have escaped notice indefinitely can now be flagged within days or weeks of publication, placing pressure on journals to investigate and resolve concerns transparently.

The handling of the investigation followed a sequence that has become fairly standard among major publishers. Following publication, concerns were raised about the integrity of the images in the published figures. The journal then contacted the authors and requested the underlying raw data or a satisfactory explanation. When neither was provided, the editors concluded that they could no longer have confidence in the findings. This step is critical: raw data serves as the foundation upon which published conclusions rest, and its absence prevents any independent verification of whether the reported results were genuine, erroneous, or fabricated. In cases where authors promptly supply original data files that resolve the questions raised, papers may be corrected rather than retracted. The inability or unwillingness to produce such data almost invariably leads to the more severe outcome.

Retraction notices serve several purposes within the scientific ecosystem. They formally detach an author’s name from claims that can no longer be trusted, they warn other researchers against building future work on unreliable results, and they create a permanent public record of the concerns. Databases maintained by the research community track retractions across the scientific literature, and indexed articles are typically flagged so that readers encountering the original paper will be alerted to its retracted status. Notably, a retraction is not always an accusation of deliberate misconduct. Errors can arise from honest mistakes, poor laboratory record-keeping, or inadequate oversight of collaborators. However, when authors cannot produce raw data to resolve legitimate questions, the distinction between error and misconduct becomes less important than the practical reality that the findings cannot be trusted.

For the field of botanical drug research, the episode carries particular weight. Natural product oncology occupies a delicate position in science. On one hand, many of the most effective anticancer drugs in clinical use derive from plants, and there is genuine biochemical logic to screening plant extracts for activity against cancer cells. On the other hand, the field has historically attracted exaggerated claims and treatments promoted to vulnerable patients without adequate evidence. Oleander in particular has been marketed in various unregulated forms as an alternative cancer remedy despite limited clinical evidence of benefit and known toxicity concerns, as the plant contains cardiac glycosides that can be dangerous at sufficient doses. Rigorous, well-documented research is essential for separating genuine therapeutic potential from unsubstantiated hope, and retractions of flawed studies make that task harder by muddying the evidentiary record.

The six-year interval between the original publication and the retraction notice may seem lengthy, but it is not unusual. Investigations of potential image integrity problems involve correspondence among editors, authors, institutional officials, and sometimes external experts. Authors must be given opportunities to respond, institutions may conduct their own inquiries, and publishers typically require approval from senior editorial leadership before issuing a formal notice. In this case, the retraction was approved by the Chief Editors of Frontiers in Pharmacology together with the Chief Executive Editor of Frontiers, and the authors received communication about the decision and an opportunity to respond, with that exchange recorded by the publisher. These procedural safeguards exist to ensure fairness, even though they extend the timeline considerably.

For patients and clinicians who may have encountered the original findings, the retraction is a clear signal that the reported results should no longer be relied upon. Claims that a botanical extract inhibited glioblastoma growth, reduced Akt/mTOR activity, and modulated stem-like cell properties cannot be considered established science following this decision. Individuals considering oleander-based products for cancer treatment should be aware that this study’s conclusions have been withdrawn, that no robust clinical evidence supports such use, and that oleander preparations carry real risks of toxicity. Patients facing glioblastoma are best served by discussing evidence-based treatment options with their oncology teams rather than pursuing remedies based on research that has since been invalidated.

The episode also illustrates why the reproducibility of scientific findings depends so heavily on data transparency. Journals and funding agencies have increasingly required authors to deposit raw data, share reagents, and document their methods in sufficient detail for independent replication. When raw data exists and is available, disputed results can often be resolved quickly, either confirming the original findings or revealing honest analytical errors. When it does not, the scientific community is left with results that cannot be verified, and the safest course is to remove them from the literature. The fact that the editors here cite the lack of raw data as central to their decision highlights how data availability has become a cornerstone of research integrity rather than an optional courtesy.

Finally, the retraction demonstrates the collective nature of scientific self-correction. A vigilant outside reader, a journal willing to investigate, editorial leadership willing to act, and a formal notice that permanently documents the outcome all played roles in the process. Science advances not only through new discoveries but through the deliberate removal of findings that fail to withstand scrutiny. While each retraction represents a disappointment, the system that identifies and publicizes them is functioning as intended, protecting the reliability of the published record on which future research and, ultimately, patient care depend.

Subject of Research: Retraction of a 2020 Frontiers in Pharmacology study on the botanical drug PBI-05204 for glioblastoma

Article Title: Retraction: The botanical drug PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of human glioblastoma, reduces Akt/mTOR activities, and modulates GSC cell-renewal properties

Article References: Frontiers Editorial Office (2026). Retraction: The botanical drug PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of human glioblastoma, reduces Akt/mTOR activities, and modulates GSC cell-renewal properties. Frontiers in Pharmacology, 17, Article 2021904. https://doi.org/10.3389/fphar.2026.2021904

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.2021904

Keywords: PBI-05204, Nerium oleander, glioblastoma, retraction, research integrity, Frontiers in Pharmacology, image manipulation, Akt/mTOR pathway, glioma stem cells, botanical drug, supercritical CO2 extract, raw data